---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Glucocorticoids and calcineurin inhibitors"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Glucocorticoids and calcineurin inhibitors. Topics: Immunosuppression in primary and secondary FSGS: KDIGO 2021 glomerular diseases guideline, Treatment resistance in genetic forms of FSGS: KDIGO 2021 glomerular diseases guideline, Response to cyclosporine or mycophenolate mofetil with dexamethasone by APOL1 genotype: FSGS Clinical Trial, Limits of glucocorticoids and calcineurin inhibitors in FSGS: review of burden, and 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/glucocorticoids-and-calcineurin-inhibitors"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Glucocorticoids and calcineurin inhibitors

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Glucocorticoids and Calcineurin Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

### Immunosuppression in primary and secondary FSGS: KDIGO 2021 glomerular diseases guideline

> “Practice Point 6.2.1.1: Immunosuppression should not be used in adults with FSGS of undetermined cause (FSGS-UC), or in those with secondary FSGS.”
> “Recommendation 6.2.2.1: We recommend that high-dose oral glucocorticoids be used as the first-line immunosuppressive treatment for primary FSGS (1D).”
> “Practice Point 6.2.2.2: Initial high-dose glucocorticoids should be continued until complete remission is achieved, or as tolerated by patients up to a maximum of 16 weeks, whichever is earlier.”
> “Recommendation 6.3.1.1: For adults with steroid-resistant primary FSGS, we recommend that cyclosporine or tacrolimus be given for”
> “rather than continuing with glucocorticoid monotherapy or not treating (1C).”
> “Practice Point 6.3.3.1: Adults with steroid-resistant primary FSGS who respond to CNI treatment should receive CNIs for a minimum of 12 months to minimize the risk of relapses (Figure 55).”
> “There is no evidence or a priori rationale justifying the use of glucocorticoids or other immunosuppressive drugs in this population, and the potential for harm of such treatment is clear.”

Source: [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf)

<a id="topic-2.2.2.1.4-2"></a>

### Treatment resistance in genetic forms of FSGS: KDIGO 2021 glomerular diseases guideline

> “Although the majority of adults with primary FSGS respond to immunosuppression, treatment resistance is a common feature in genetic forms of FSGS, and in particular, resistance to glucocorticoid therapy is a consistent finding in all forms of genetic FSGS.”
> “Moreover, the discovery of genetic variants in this group should prompt a discussion on discontinuing further immunosuppression treatment.”

Source: [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf)

<a id="topic-2.2.2.1.4-3"></a>

### Response to cyclosporine or mycophenolate mofetil with dexamethasone by APOL1 genotype: FSGS Clinical Trial

> “The FSGS Clinical Trial involved 138 children and young adults who were randomized to cyclosporin or mycophenolate mofetil plus pulse oral dexamethasone with a primary outcome of proteinuria remission.”
> “APOL1 risk genotype did not affect response to either treatment regimen. Individuals with the risk genotype were more likely to progress to ESRD (P<0.01).”
> “At present, however, there are no data that would indicate that aggressive treatment with available agents retards progressive kidney function loss in these high-risk individuals.”

Source: [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/)

<a id="topic-2.2.2.1.4-4"></a>

### Limits of glucocorticoids and calcineurin inhibitors in FSGS: review of burden

> “Until recently, no medicines had been approved by the FDA or European Medicines Agency, with management focused on supportive care and proteinuria reduction.”
> “Available treatments, such as glucocorticoids or calcineurin inhibitors, are limited in efficacy and safety.”

Source: [Bensink et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42101820/)

<a id="topic-2.2.2.1.4-5"></a>

### Role of conventional immunosuppression in APOL1 kidney disease as a research question

> “Is there a role for conventional treatment of FSGS and other glomerular diseases (calcineurin inhibitors, cytotoxic agents) in patients with APOL1 high-risk genotypes?”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
